Skip to main content

glp 1 obesity drugs

2 articles found

Novo Nordisk Crashes 15% as Next-Gen Obesity Drug Loses

The weight-loss drug wars reached a decisive inflection point on Monday as Novo Nordisk's shares plummeted nearly 16% — wiping roughly $27 billion off its market capitalization in a single session — after its much-anticipated next-generation obesity treatment CagriSema failed to prove it was at least as effective as Eli Lilly's tirzepatide in a pivotal 84-week clinical trial. The Danish drugmaker's stock fell to $40.07 per share, hitting its lowest level since June 2021 and marking a staggering decline of more than 57% from its 52-week high of $93.80. The REDEFINE 4 Phase III trial, which was designed to demonstrate non-inferiority to Lilly's blockbuster ingredient — the active compound behind both Mounjaro and Zepbound — instead showed CagriSema delivering 23% weight loss at 84 weeks compared to 25.5% for tirzepatide. For a company that once dominated the GLP-1 obesity market with Ozempic and Wegovy, the result represents a potentially existential competitive setback that reshapes the landscape of a market projected to exceed $100 billion by the end of the decade. Meanwhile, Eli Lilly surged 4.5% to $1,055.25, approaching its $995.5 billion market capitalization as it simultaneously launched a new multi-dose KwikPen form of Zepbound offering a full month of treatment in a single device at $299 per month — a calculated one-two punch of clinical superiority and patient convenience that further cements its dominant position.

Novo NordiskEli LillyCagriSema

Novo Nordisk Crashes 47% From Peak as Obesity Drug Empire

Novo Nordisk, the Danish pharmaceutical giant that once seemed invincible atop the global obesity drug market, is now fighting on every front simultaneously — and investors are voting with their feet. Shares of Novo Nordisk (NVO) traded at $49.57 on Monday, down a staggering 47% from their 52-week high of $93.80, as the company grapples with intensifying competition from Eli Lilly, a legal war against compounding pharmacies, and a 2026 financial outlook that shocked Wall Street with the prospect of declining revenues. The scale of the reversal is remarkable. Just months ago, Novo was the most valuable company in Europe and the undisputed leader in GLP-1 weight loss treatments. Today, its market capitalization has been cut roughly in half to $220.4 billion, while rival Eli Lilly commands a valuation north of $932 billion — more than four times Novo's size. In the span of a single month, NVO shares plunged 21%, with a single-day drop of 14% followed by violent snapback rallies, as investors tried to parse whether the company's problems are temporary growing pains or signs of a structural decline. The catalyst for the latest rout was Novo's 2026 guidance, released alongside otherwise solid fourth-quarter results on February 4. While Q4 revenue came in at DKK 78.4 billion with a 34% net profit margin — numbers most companies would celebrate — the forward outlook told a different story entirely. On an adjusted basis, Novo expects sales and operating profit to decline 5% to 13% at constant exchange rates in 2026, a dramatic contrast to Eli Lilly's guidance calling for 25% sales growth in the same period.

Novo NordiskNVOEli Lilly